Skip to content

13F-HR filed by Bain Capital Life Sciences Investors, LLC

Bain Capital Life Sciences Investors, LLC filed this 13F-HR for the quarter ended 2020-12-31, filed 2021-02-16, with 26 holding rows worth $1,592,801,000.

Accession
0000950123-21-002146
Filed
2021-02-16
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q4 2020

A holdings report, 26 entries on the cover page, a total value of $1,592,801,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $1,592,801,000 with VALUE read as thousands by filing date, 13F file number 028-18477. The quarter's positions are built on this report. The resolved quarter.

Other managers

  • included managerBain Capital Life Sciences Partners, LP 028-18476
  • included managerBain Capital Life Sciences Fund, L.P. 028-18478
  • included managerBC SW, LP 028-20270
  • included managerBain Capital Life Sciences Investors II, LLC
  • included managerBain Capital Life Sciences Fund II, L.P.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
SPRINGWORKS THERAPEUTICS INC85205L107COM7,281,307$528,040,000thousands by filing date
ATEA PHARMACEUTICALS INC04683R106COMMON STOCK5,615,659$234,622,000thousands by filing date
ARCUTIS BIOTHERAPEUTICS INC03969K108COM3,979,292$111,937,000thousands by filing date
Mersana Therapeutics Inc59045L106Common Stock3,445,667$91,689,000thousands by filing date
ANNEXON INC03589W102COM3,241,628$81,138,000thousands by filing date
DICERNA PHARMACEUTICALS INC253031108COM3,080,237$67,858,000thousands by filing date
SYROS PHARMACEUTICALS INC87184Q107COM5,785,036$62,768,000thousands by filing date
C4 THERAPEUTICS INC12529R107COM STK1,642,209$54,406,000thousands by filing date
SOLID BIOSCIENCES INC COM NEW83422E105Stock7,060,353$53,517,000thousands by filing date
DYNAVAX TECHNOLOGIES CORP268158901COM NEW10,895,773$48,486,000thousands by filing date
NURIX THERAPEUTICS INC67080M103COMMON STOCK1,284,314$42,228,000thousands by filing date
CONSTELLATION PHARMACEUTICALS INC.210373106Common Stock1,400,000$40,320,000thousands by filing date
APTINYX INC03836N103COM8,891,758$30,765,000thousands by filing date
KYMERA THERAPEUTICS INC501575104COM479,605$29,735,000thousands by filing date
AEGLEA BIOTHERAPEUTICS INC00773J103COM2,700,000$21,249,000thousands by filing date
MARINUS PHARMACEUTICALS INC56854Q101COM1,431,058$17,459,000thousands by filing date
CRINETICS PHARMACEUTICALS INC COM22663K107Stock1,071,428$15,118,000thousands by filing date
THERAPEUTICS ACQUISITION COR88339T103COM CL A1,000,000$13,920,000thousands by filing date
ARYA SCIENCES ACQUISITION COG3166W106COM CL A1,000,000$10,850,000thousands by filing date
X4 Pharmaceuticals, Inc.98420X103COM1,648,485$10,600,000thousands by filing date
SAVARA INC805111101COM5,128,593$5,898,000thousands by filing date
BCTG ACQUISITION CORP05492W103COM500,000$5,720,000thousands by filing date
BCLS ACQUISITION CORPG0904B105CMN487,500$5,431,000thousands by filing date
FRAZIER LIFESCIENCES ACQU CORP UNIT EXP 120925G3710A121Stock300,000$3,114,000thousands by filing date
JIYA ACQUISITION CORP47760M102CMN300,000$3,090,000thousands by filing date
MOONLAKE IMMUNOTHERAPEUTICSG4444C102COM250,000$2,843,000thousands by filing date

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0000950123-21-002146this filing2021-02-16acceptance time not in the bulk data set